Open-Label absorption, distribution, metabolism, excretion (ADME) and pharmacokinetics (PK) following a Single Oral Dose of AZD1236 in Healthy Male Subjects
Study identifier:D4260C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics following a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
14C-AZD1236
Sex
Male
Actual Enrollment
4
Study type
Interventional
Age
50 Years - 65 Years
Date
Study Start Date: 01 Oct 2009
Primary Completion Date: -
Estimated Study Completion Date: 01 Nov 2009
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 14C-AZD1236 | Drug: 14C-AZD1236 Oral solution 1mg/mL |
Contacts
Investigators
Principal Investigator
AstraZeneca CPU Medical Director
AstraZeneca
